Search for content, post, videos

AlzeCure selects candidate drug and enters next phase with Alzstatin

AlzeCure Pharma has chosen a candidate drug (CD) and started the preclinical development phase with the company’s preventive and disease-modifying candidate drug Alzstatin ACD680.

ACD680 is being developed within AlzeCure’s Alzstatin platform, with the aim of developing a preventive and disease-modifying drug for the early treatment of Alzheimer’s disease. In the project, a CD has now been selected which will continue into the preclinical development program, which includes preclinical safety and tolerability studies, as well as formulation work and stability testing, states the company.

”We are very pleased to have begun preclinical development with ACD680. We hereby build further on the communicated strategy to strengthen the project portfolio with the development of several candidates in parallel and also demonstrate AlzeCure’s capacity in terms of development and delivery. With the increased interest in the Alzheimer field, we see exciting commercial opportunities for Alzstatin going forward,” says AlzeCure’s CEO Martin Jönsson.

A gamma-secretase modulator

ACD680 is a so-called gamma-secretase modulator (GSM), which constitutes a promising class of small-molecule Aβ42-lowering anti-amyloidogenic substances for preventive and disease-modifying treatment of Alzheimer’s disease. The GSM thereby affects the production of the very building block of the harmful amyloid aggregates and exhibits several key properties that distinguish it from antibody treatments, including that it can be taken in tablet form, easily crosses the blood-brain barrier and can be produced more cost-effectively.

”With Alzstatin, we want to offer a preventive and disease-modifying treatment against Alzheimer’s in the form of an oral therapy, which is non-invasive for patients. In addition to affecting an important disease mechanism, ACD680 also derives from a new series of molecules that, among other things, are expected to provide benefits from a patent perspective, with a significantly longer patent period,” says Gunnar Nordvall, project leader and Director of Medicinal Chemistry at AlzeCure.

Photo of Martin Jönsson: Jenny Lagerqvist/AlzeCure Pharma